What compounds target MELK?

BiohacksAI has identified 41 compounds that interact with MELK (maternal embryonic leucine zipper kinase). Top compounds include: imatinib, foretinib, tozasertib, ponatinib, ruxolitinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is MELK (maternal embryonic leucine)?

MELK is maternal embryonic leucine zipper kinase. It is a molecular target for 41 compounds documented in PubMed bioassay data. UniProt ID: Q14680. NCBI Gene ID: 9833.

MELK

MOLECULAR TARGET

maternal embryonic leucine zipper kinase

UniProt: Q14680 NCBI Gene: 983341 compounds

MELK (maternal embryonic leucine zipper kinase) is targeted by 41 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MELK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	imatinib	5.47	236
2	foretinib	4.34	76
3	tozasertib	4.33	75
4	ponatinib	4.26	70
5	ruxolitinib	4.23	68
6	midostaurin	3.85	46
7	brigatinib	3.81	44
8	neratinib	3.66	38
9	fasudil	3.66	38
10	nintedanib	3.61	36
11	bms 387032	3.47	31
12	tae 684	3.43	30
13	fedratinib	3.40	29
14	mln 8054	3.33	27
15	dabrafenib	3.30	26
16	dovitinib	3.09	21
17	at 9283	3.09	21
18	lestaurtinib	3.04	20
19	pf 03758309	3.00	19
20	danusertib	2.94	18
21	k 252a	2.83	16
22	milciclib	2.77	15
23	pf 00562271	2.77	15
24	hesperadin	2.77	15
25	crenolanib	2.71	14
26	kw 2449	2.64	13
27	gsk 690693	2.64	13
28	ast 487	2.56	12
29	defactinib	2.48	11
30	azd 7762	2.30	9
31	su 014813	2.20	8
32	bgt 226 free base	2.20	8
33	cyc 116	2.08	7
34	enzastaurin	2.08	7
35	su 11652	2.08	7
36	uprosertib	1.95	6
37	hydroxyfasudil [Supplementary Concept]	1.10	2
38	sp600125	1.10	2
39	ha1004	0.69	1
40	Harmine Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is	0.69	1
41	pictilisib	0.69	1

About MELK as a Drug Target

MELK (maternal embryonic leucine zipper kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 41 compounds with documented MELK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MELK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.